TH104, the Company's lead candidate for moderate-to-severe pruritus in chronic liver disease, showed no opioid withdrawal ...

Alzheimer’s patients using the SinaptiStim system experienced a 44% reduction in disease progression over 12 months.

As the world of neurodegenerative disease drug development continues to be roiled by controversies, one company has taken a ...

Medical collab PARASOL broadens potential surrogate endpoints for FDA approval of treatments for rare kidney disease.

We welcome the recognition that Life Sciences, the scientific study of living organisms including humans, is a key target for ...

Vera Therapeutics has shown the effect of atacicept on kidney function in patients with immunoglobulin A nephropathy persists ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its ...

The wildfire that killed 102 erupted from an earlier brushfire, sparked by downed power lines, that firefighters believed ...

The phase III PALOMA-3 study compared subcutaneous versus intravenous amivantamab in ... Burns Advarra, Amgen, AstraZeneca, ...

LUND, SE / ACCESSWIRE / October 30, 2024 / Alligator Bioscience (STO:ATORX) Lund, Sweden - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces participation in the following conferences dur ...